GURNEE, IL, February 27, 2026 /24-7PressRelease/ -- Creative Biotherapeutics, LLC announced continued progress in the preclinical development of CBT300, an investigational biologic therapeutic candidate. The program is being advanced through research, validation, and regulatory preparation focused on mechanisms associated with drug resistance, immune evasion, recurrence, and metastasis.

The company is led by Anita Davidson, DPT, a healthcare professional with decades of experience supporting patient recovery and long-term function, and her husband and scientific collaborator, Dr. Don Davidson, a biochemist with more than thirty-five years of experience in drug development, oncology research, and complex protein structure science.

Origin and Mission

For Anita Davidson, the work is rooted in clinical reality and patient experience. She recently lost a sixteen-year-old patient to a form of brain cancer that returned rapidly despite treatment.

"There are losses that stay with you," Davidson said. "You remember the families, the hopes, and the urgency. That child is a reason I keep working."

Later, Davidson added, "We just could not watch another child die."

The company has not announced initial clinical indications for CBT300.

Dr. Don Davidson said the company's development efforts are guided by a focus on biological mechanisms that contribute to treatment failure and disease return.

"Cancer outcomes are often shaped by recurrence and resistance," he said. "Our development work focuses on mechanisms associated with relapse and treatment escape so future therapies can be evaluated with that reality in mind."

Fast Facts: Creative Biotherapeutics and CBT300

Company: Creative Biotherapeutics, LLC
Program: CBT300
Category: Investigational biologic therapeutic candidate
Development stage: Preclinical research and validation, with ongoing regulatory preparation
Scientific focus: Mechanisms associated with drug resistance, immune evasion, recurrence, and metastasis
Goal: Advance toward FDA-regulated clinical trials through an evidence-based development pathway
Intellectual property: The company reports issued and pending patents related to its platform and lead program

Mechanism-Informed Development Focus

CBT300 is being developed as a multi-mechanism biologic candidate intended to be evaluated for its potential to interfere with:

· Drug-resistance pathways

· Immune-evasion mechanisms

· Cellular processes associated with recurrence and metastasis

The company stated that research and validation are ongoing and that development decisions are guided by a disciplined, evidence-based approach as it progresses through regulatory preparation.

Davidson also emphasized tolerability as an important development consideration in oncology.

"Patients and families live with the full burden of treatment," Davidson said. "We want development pathways that respect patients and are guided by real-world experience."

Development Path Toward Clinical Evaluation

Creative Biotherapeutics is preparing remaining components required to support advancement toward FDA-regulated clinical trials, including continued research, validation, and regulatory readiness.

"We are working diligently toward entering clinical trials," Dr. Davidson said. "Progress has to be earned through data, discipline, and integrity."

Public Information and Collaboration

Creative Biotherapeutics is sharing information publicly to support awareness among patients, clinicians, and members of the scientific and healthcare communities regarding CBT300 and its development progress.

The company welcomes mission-aligned collaboration inquiries related to the responsible development of CBT300 and the advancement of science-driven oncology solutions, including:

· Research collaborations

· Clinical and scientific partnerships

· Development and regulatory alignment opportunities

Collaboration inquiries can be directed here with a brief description of organizational role and interest area.

For more information, visit the official website.

About Creative Biotherapeutics, LLC

Creative Biotherapeutics, LLC is a biotechnology company focused on developing investigational biologic therapeutic candidates designed to address challenges in cancer treatment, including drug resistance, immune evasion, recurrence, and metastasis. The company is advancing its lead program, CBT300, through research, validation, and regulatory preparation with the goal of improving outcomes for patients facing aggressive cancers.

About CBT300

CBT300 is an investigational biologic therapeutic candidate under development by Creative Biotherapeutics designed to evaluate its potential to address mechanisms associated with cancer drug resistance, immune evasion, recurrence, and metastasis. CBT300 is being advanced through preclinical validation and regulatory preparation with the goal of entering FDA-regulated clinical trials.

Important Notice

CBT300 is investigational and has not been approved by the U.S. Food and Drug Administration. Forward-looking statements are subject to risks and uncertainties.

Media Contact

Creative Biotherapeutics, LLC
Attention: Media Relations
68 Ambrogio Drive, Suite 101
Gurnee, IL 60031
Email: Click here
Website: Click here

This contant was orignally distributed by 24-7 Press Release. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Clinician Anita Davidson and Biochemist Dr. Don Davidson Advance CBT300, an Investigational Biologic Candidate for Cancer Recurrence and Drug Resistance.